According to the Zhitong Finance App, BeiGene (688235.SH) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 22.22 billion yuan, an increase of 26.84% over the previous year. Achieved net profit attributable to shareholders of listed companies of 3.271 billion yuan, an increase of 627.15% over the previous year. Achieved net profit of 2,918 billion yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 1017.59% over the previous year.
In the first half of 2026, product revenue was 21.797 billion yuan, and product revenue for the same period last year was 17.360 billion yuan. The increase in product revenue was mainly due to sales growth of Baiyuze® (zebutinib), products authorized by Amgen and Baizean® (tiralizumab).
In the first half of the year, Baiyuze®'s global sales totaled 16.127 billion yuan, an increase of 28.7% over the previous year. Among them, US sales totaled 11.390 billion yuan, an increase of 27.2% over the previous year. In the first half of 2026, Baizeon®'s global sales totaled 2,984 billion yuan, an increase of 12.9% over the previous year. In the first half of 2026, sales of Amgen's authorized products were 2,065 billion yuan, an increase of 19.6% over the previous year.
Baiyueze® is the most widely approved BTK inhibitor in the world. It is also the only BTK inhibitor that is flexible and can be administered once or twice daily. The global Phase 3 ALPINE trial of Baiyueze® “head-to-head” compared to Yike® (ibutinib) for treating adult patients with recurrent or refractory (R/R) chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) showed continued progression-free survival (PFS) benefits and a lower incidence of cardiovascular events. Baiyuze® specification updates have been approved in the US, EU and UK to include the PFS efficacy results obtained in the Phase 3 ALPINE trial (median follow-up time of 29.6 months), further consolidating the position of Baiyuze® as the preferred BTK inhibitor. The company announced 78-month long-term follow-up data from the Phase 3 SEQUOIA trial at the 2026 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meeting, which continued to demonstrate the continued benefits of Baiyuze® in treating adult patients with CLL/SLL at the first treatment. The company announced positive results from the Phase 3 MANGROVE trial: Baiyueze® combined with rituximab, compared with bendamustine plus rituximab, showed excellent PFS efficacy in previously untreated adult patients with mantle cell lymphoma (MCL). The company expects to submit marketing applications for Baiyuze® for first-line treatment of MCL adult patients in the US, Europe, China and Japan in the second half of 2026.